Simultaneous Detection and HER2 Profiling of Circulating Breast Cancer Cells in Clinical Patients Using a Rare Cell Sorter

Mori, Tomoko; Furukawa, Atsuko; TURAN, Bilal; Ueda, Aya; Bando, Hiroko; Masuda, Taisuke; Arai, Fumihito; MATSUSAKA, SATOSHI

doi:10.21873/anticanres.15993

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The RCS can capture cells using cell size differences and stains. The RCS can automatically detect and pick-up single cells, including CTCs, using differences in staining [21,22]. However, as the capability of this novel method to recover tumor cells has been veri ed, we investigated EGFR mutation concordance between CTCs and tissue samples to test whether the collected tumor-like cells were CTCs.…”

Section: Introductionmentioning

confidence: 99%

Detection of circulating tumor cells in patients with lung cancer using a Rare Cell Sorter: a pilot study

Sugai,

Mori,

Bilal

et al. 2024

Preprint

Self Cite

View full text Add to dashboard Cite

Background We developed a Rare Cell Sorter (RCS) for collecting single cell including circulating tumor cells (CTCs). This single-institution pilot study evaluated the ability of this device to detect tumor-like cells in patients with lung cancer and confirmed their genuineness based on the epidermal growth factor receptor (EGFR) mutation concordance with tissue samples. Methods This study included patients treated for lung cancer from September 2021 to August 2022 in University of Tsukuba Hospital. Peripheral blood samples were obtained before surgery or during periodic medical checks for patients treated with drugs. We used the RCS to capture cells based on size. The cells were stained, and the Hoechst-positive, CD45-negative, and epithelial celladhesion molecule (EpCAM)- positive cells were defined as CTCs, were collected. The presumptive CTCs were counted and tested using digital droplet polymerase chain reaction for EGFR mutations and compared with the tissue EGFR status to check concordance. Results Eighteen patients were included in this study and CTCs were detected in 6 patients (33%). The CTCs from three patients showed EGFR mutation, and the EGFR mutation status of CTCs concorded with that of tissue samples in 83% of the cases (5/6). Only one CTC showed a different status from the tissue, and the concordance rate of EGFR status between CTCs and the tissue was 96% (24/25). Conclusion The ability of the RCS to detect CTCs in patients with lung cancer was demonstrated based on the concordance of EGFR status in this pilot study. This novel hybrid method of CTC recovery using the RCS has the potential to recover a wide range of CTCs regardless of EpCAM. Further validation through a large-scale study is needed.

show abstract

Section: Introductionmentioning

confidence: 99%